RT Journal Article
SR Electronic
T1 Therapeutic pulmonary metastasectomy for colorectal cancer should be chosen in any disease-free interval, size of tumor, and carcinoembryonic antigen level
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP p2422
VO 38
IS Suppl 55
A1 Masao Naruke
YR 2011
UL http://erj.ersjournals.com/content/38/Suppl_55/p2422.abstract
AB Aims: We retrospectively review our experience of pulmonary resection of metastases from colorectal cancer, in order to document postoperative clinical outcome and survival.Methods: From 2003 to 2010, in 16 patients, 19 pulmonary metastases from colorectal cancer were therapeutically resected in our hospital (9 were rectal and 7 were colon; 10 males and 6 females; mean age 66.3 years). The indication for these metastasectomies was based on Thomford's advocateship. They were analyzed retrospectively to calculate prognosis, and reviewed to verify their disease- free interval (DFI: interval between resection of primary tumor and diagnosis of lung metastases), size of largest resected metastases, pre-metastasectomy carcinoembryonic antigen (CEA) level with the reported prognostic factor. After lung metastasectomy, patients were followed up for 2- 95 months (median: 45.5 months).Results: There was no operative mortality. Complications occurred in 3 out of 16 patients (19%) but were major only in 1 (6%). Overall, 3- and 5- year survival rates, from the date of pulmonary metastasectomy were 78.6% and 48.1%, respectively.The mean of DFI was 19.9 months (0- 99), the mean size of largest resected metastases was 22.6mm (9- 60), and the mean of pre-metastasectomy CEA level was 5.1 ng/ml (1.0- 32). These factors were not associated with longer survival.Conclusion: Based on our experience, a good prognosis can be expected after therapeutic pulmonary metastasectomy for colorectal cancer regardless of factors such as DFI, size of metastasis, pre-metastasectomy CEA level.